ID24096A - Metode untuk menghambat resorpsi tulang - Google Patents

Metode untuk menghambat resorpsi tulang

Info

Publication number
ID24096A
ID24096A IDW20000114A ID20000114A ID24096A ID 24096 A ID24096 A ID 24096A ID W20000114 A IDW20000114 A ID W20000114A ID 20000114 A ID20000114 A ID 20000114A ID 24096 A ID24096 A ID 24096A
Authority
ID
Indonesia
Prior art keywords
methods
disclosed
obstacling
resorts
bone
Prior art date
Application number
IDW20000114A
Other languages
English (en)
Indonesian (id)
Inventor
Arthur C Ii Santora
Anastasia G Daifotis
A John Yates
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID24096(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ID24096A publication Critical patent/ID24096A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
IDW20000114A 1997-07-22 1998-07-17 Metode untuk menghambat resorpsi tulang ID24096A (id)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Publications (1)

Publication Number Publication Date
ID24096A true ID24096A (id) 2000-07-06

Family

ID=27451690

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000114A ID24096A (id) 1997-07-22 1998-07-17 Metode untuk menghambat resorpsi tulang

Country Status (31)

Country Link
EP (5) EP1132088A3 (el)
JP (2) JP3479780B2 (el)
KR (3) KR20030097610A (el)
CN (3) CN1602879A (el)
AT (2) ATE357921T1 (el)
AU (1) AU8493698A (el)
BG (1) BG66282B1 (el)
BR (1) BR9810779A (el)
CA (1) CA2294595C (el)
CY (2) CY1107535T1 (el)
DE (6) DE122007000063I1 (el)
DK (2) DK0998292T3 (el)
EA (1) EA004544B2 (el)
EE (1) EE05603B1 (el)
ES (3) ES2253136T1 (el)
HK (5) HK1024166A1 (el)
ID (1) ID24096A (el)
IL (1) IL133535A0 (el)
IS (3) IS5315A (el)
LU (2) LU91222I2 (el)
NL (2) NL300223I1 (el)
NO (1) NO20000323L (el)
NZ (1) NZ501807A (el)
PL (1) PL195272B1 (el)
PT (2) PT1175904E (el)
SG (2) SG109478A1 (el)
SI (1) SI0998292T1 (el)
SK (1) SK932000A3 (el)
TR (1) TR200000145T2 (el)
UY (1) UY25950A1 (el)
WO (1) WO1999004773A2 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038694A1 (fr) * 1998-12-25 2000-07-06 Yamanouchi Pharmaceutical Co., Ltd. Compositions de medicaments servant a traiter les lesions osseuses dans le myelome multiple
PL351674A1 (en) * 1999-05-21 2003-05-19 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
ES2337545T3 (es) * 1999-07-19 2010-04-27 Toray Industries, Inc. Farmacos para enfermedades periodontales.
AU2270101A (en) * 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
WO2001046040A1 (en) 1999-12-20 2001-06-28 Merck & Co., Inc. Blister package for pharmaceutical treatment card
MXPA02009924A (es) * 2000-04-07 2004-08-19 Univ Texas Composiones unicas de fosfolipidos de ion anfoterico y bisfosfonatos y uso de las composiciones como sistemas de suministro de bisfosfato con toxicidad gi reducida.
CZ301972B6 (cs) 2000-06-20 2010-08-18 Novartis Ag Farmaceutické prostredky s obsahem kyseliny zoledronové pro lécení stavu s abnormálne zvýšeným kostním obratem
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
CN100551377C (zh) * 2002-05-10 2009-10-21 弗·哈夫曼-拉罗切有限公司 用于治疗和预防骨质疏松症的二膦酸
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
BRPI0414565A (pt) * 2003-09-19 2006-11-07 Pfizer Prod Inc composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
CA2622322A1 (en) * 2005-09-16 2007-03-22 Selamine Ltd Bisphosphonate formulation
ES2716525T3 (es) * 2010-12-06 2019-06-13 Effrx Pharmaceuticals Sa Formulaciones de bisfosfonatos efervescentes estables con características de solubilización rápida
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
DE59202126D1 (de) * 1991-07-01 1995-06-14 Gergely Gerhard Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung.
AU661080B2 (en) * 1991-11-22 1995-07-13 Warner Chilcott Company, Llc Risedronate delayed-release compositions
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
ES2111163T3 (es) * 1992-06-30 1998-03-01 Procter & Gamble Pharma Uso de fosfonatos para el tratamiento de la osteoporosis.
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
JPH11506750A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 慢性関節リウマチに係わる骨欠損に対するビスホスホネート療法
EP0939624B1 (en) * 1996-05-17 2003-12-17 Merck & Co., Inc. Effervescent bisphosphonate formulation

Also Published As

Publication number Publication date
CY2007022I2 (el) 2012-01-25
ES2164447T3 (es) 2002-02-16
LU91364I2 (fr) 2007-11-12
SK932000A3 (en) 2000-09-12
ATE357921T1 (de) 2007-04-15
CN1299689C (zh) 2007-02-14
ES2269014T3 (es) 2007-05-01
DK1175904T3 (da) 2007-05-07
IL133535A0 (en) 2001-04-30
PL195272B1 (pl) 2007-08-31
ES2269014T1 (es) 2007-04-01
EP1175904A2 (en) 2002-01-30
JP2005068010A (ja) 2005-03-17
KR20030097611A (ko) 2003-12-31
CN1602879A (zh) 2005-04-06
BR9810779A (pt) 2000-07-25
IS7230A (is) 2004-04-21
EA004544B1 (ru) 2004-06-24
EA200000151A1 (ru) 2000-10-30
NL300223I1 (nl) 2006-04-03
CA2294595A1 (en) 1999-02-04
EP0998292A2 (en) 2000-05-10
EP0998292B1 (en) 2001-11-21
WO1999004773A3 (en) 1999-04-15
EP1175903A2 (en) 2002-01-30
DE69803291T2 (de) 2002-08-08
SI0998292T1 (en) 2002-04-30
CY2007022I1 (el) 2012-01-25
NO20000323L (no) 2000-03-20
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
PT998292E (pt) 2002-04-29
DE69837450T2 (de) 2007-08-23
KR20010022110A (ko) 2001-03-15
UY25950A1 (es) 2000-09-29
CN1602880A (zh) 2005-04-06
WO1999004773A9 (en) 1999-10-28
DK0998292T3 (da) 2002-05-13
LU91222I2 (fr) 2006-04-18
BG104093A (en) 2000-10-31
IS5315A (is) 1999-12-21
EP1175904B8 (en) 2007-05-09
EP1151752A2 (en) 2001-11-07
DE69803291D1 (de) 2002-02-21
HK1024166A1 (en) 2000-10-05
HK1042232A1 (zh) 2002-08-09
TR200000145T2 (tr) 2000-05-22
BG66282B1 (bg) 2013-01-31
CN1166365C (zh) 2004-09-15
EP1151752A3 (en) 2002-12-18
DE01201913T1 (de) 2007-02-08
EE05603B1 (et) 2012-12-17
HK1040495A1 (zh) 2002-06-14
PL338635A1 (en) 2000-11-06
NZ501807A (en) 2003-02-28
HK1040494A1 (zh) 2002-06-14
EP1175904A3 (en) 2002-12-18
SG109478A1 (en) 2005-03-30
DE122006000009I1 (de) 2006-06-14
KR100391732B1 (ko) 2003-07-16
EP1175903A3 (en) 2002-12-18
KR20030097610A (ko) 2003-12-31
EP1175904B1 (en) 2007-03-28
WO1999004773A2 (en) 1999-02-04
JP2002502433A (ja) 2002-01-22
EE200000040A (et) 2000-10-16
CA2294595C (en) 2001-08-21
CN1265035A (zh) 2000-08-30
EP1132088A3 (en) 2002-04-24
DE122007000063I1 (de) 2007-12-20
HK1042230A1 (zh) 2002-08-09
EP1132088A2 (en) 2001-09-12
NL300292I1 (nl) 2007-11-01
IS7231A (is) 2004-04-21
DE69837450D1 (de) 2007-05-10
CY1107535T1 (el) 2012-01-25
ES2253136T1 (es) 2006-06-01
DE01201911T1 (de) 2007-10-18
EA004544B2 (ru) 2006-12-29
JP3479780B2 (ja) 2003-12-15
AU8493698A (en) 1999-02-16
PT1175904E (pt) 2007-04-30
ATE209037T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
LU91364I2 (fr) Alendronate de sodium /colécalciférol
NZ545804A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
NZ272608A (en) Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
BR0309691A (pt) Formulação de ibandronato em alta dose
YU1800A (sh) Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju
TWI226833B (en) Pharmaceutical composition for inhibiting bone resorption